ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 Phase 3 DESTINY-Breast04 Trial Safety Analysis: T-DXd vs. TPC in HER2-Low Unresectable and/or Metastatic BC
By
ESMO Breast Cancer 2023 Congress Coverage
FEATURING
Hope Rugo
By
ESMO Breast Cancer 2023 Congress Coverage
FEATURING
Hope Rugo
Login to view comments.
Click here to Login
